Annexon: Positive Phase 1 Results For ANX1502; ANX007 Registrational Program; Prices $125 Mln Shares
Annexon Inc. (ANNX), a clinical-stage biopharmaceutical company focused on inflammatory-related diseases, reported Wednesday positive results from the Phase 1 trial of ANX1502, its oral small molecule inhibitor of the classical … Read More